Acute undifferentiated leukemia: data on incidence and outcomes from a large population-based database. (February 2020)

• Record Type: Journal Article
• Authors: Qasrawi, Ayman; Gomes, Victor; Chacko, Charles Andrew; Mansour, Akila; Kesler, Melissa; Arora, Ranjana; Wei, Sainan; Ramlal, Reshma; Munker, Reinhold
• Is Part Of: Leukemia research. Volume 89(2020)
• Publication Date: 2020-02
• Subjects: acute -- undifferentiated -- leukemia -- incidence -- prognosis; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2020.106301
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: SEER data for acute undifferentiated leukemia (AUL) 2000- 2016 AUL is rare and occurs mostly in older patients AUL has decreased in incidence The prognosis of AUL is often poor, but has improved In the pediatric age group, the prognosis is comparable to ALL Abstract: Acute undifferentiated leukemia (AUL) is rare and defined by the absence of bona fide myeloid and lymphoid markers. Little is known about its incidence, survival and optimal management in the recent time period. Based on a case observed in our clinic, we queried the Surveillance, Epidemiology, and End Results database between 2000 and 2016. A total of 1, 888 cases of AUL were diagnosed (1.34 per million person-years). The incidence of AUL has significantly decreased over time. Compared to other acute leukemias, patients with AUL have the highest median age (74 years); in contrast to acute myeloid leukemia (AML, 65) and acute lymphoblastic leukemia (ALL, 12). Excluding patients with preexisting malignancies, 1, 444 patients with AUL were analyzed for survival. Only 35% of AUL patients had received chemotherapy. Comparatively, 94% of ALL and 71% of AML cases received chemotherapy. Among AUL patients who received chemotherapy, the median survival was 12 months as opposed to 1 month in the group who did not receive chemotherapy (or unknown status). Among adults, AUL patients had the worst prognosis, with a median overall survival (OS) of 9 months, compared to 27 months in ALL and 13 months in AML. Among children, the median OS was superior for all three groups of leukemias, the OS of AUL patients being better than in AML and very similar to ALL. On multivariate analysis, older age and time period were associated with worse outcome. We describe here the largest series of cases with AUL published to date.